TY - JOUR
T1 - Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction
AU - Wang, Tracy Y.
AU - McCoy, Lisa A.
AU - Bhatt, Deepak L.
AU - Rao, Sunil V.
AU - Roe, Matthew T.
AU - Resnic, Frederic S.
AU - Cavender, Matthew A.
AU - Messenger, John C.
AU - Peterson, Eric D.
N1 - Funding Information:
Dr Wang reports research grants to the DCRI from Eli Lilly, Daiichi Sankyo, Gilead Sciences, Glaxo Smith Kline, the American College of Cardiology, and the American Society of Nuclear Cardiology, as well as honoraria from Astra Zeneca and the American College of Cardiology. Ms McCoy, Dr Rao, Dr Resnic, Dr Cavender, and Dr Messenger have no relevant disclosures to report. Dr Bhatt discloses the following relationships: advisory board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; board of directors: Boston VA Research Institute, and Society of Cardiovascular Patient Care; chair: American Heart Association Get With The Guidelines Steering Committee; data monitoring committees: Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, and Population Health Research Institute; honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), and WebMD (CME steering committees); other: Clinical Cardiology (Deputy Editor); research funding: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi Aventis, and The Medicines Company; site co-investigator: Biotronik, St Jude Medical; trustee: American College of Cardiology; unfunded research: FlowCo, PLx Pharma, and Takeda. Dr Roe reports research funding from Eli Lilly & Company, Sanofi-Aventis, Daiichi-Sankyo, Amgen, and the FH Foundation (all significant); educational activities from Astra Zeneca and Bristol Myers Squibb (both modest); consulting (including CME) from Eli Lilly & Company, Janssen Pharmaceuticals, Elsevier Publishers (all modest), Astra Zeneca, Merck & Co., and Amgen (all significant). Dr Peterson reports receiving research grants from Lilly, Johnson & Johnson, Bristol-Myers Squibb, Sanofi-Aventis, and Merck-Schering Plough partnership, and serving as principal investigator of the data analytic center for the American Heart Association/American Stroke Association's Get With The Guidelines.
Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2016/2
Y1 - 2016/2
N2 - Background Older adults presenting with acute myocardial infarction (MI) often have multivessel coronary artery disease amenable to percutaneous coronary intervention (PCI), yet the risks of multivessel intervention may outweigh potential benefits in these patients. We sought to determine if nonculprit intervention during the index PCI is associated with better outcomes among older patients with acute MI and multivessel disease. Methods We examined 19,271 ST-segment elevation MI (STEMI) and 31,361 non-STEMI (NSTEMI) patients 65 years or older with multivessel disease in a linked CathPCI Registry-Medicare database, excluding patients with prior coronary artery bypass grafting, left main disease, or cardiogenic shock. Using inverse probability-weighted propensity adjustment, we compared mortality between patients receiving culprit-only vs multivessel intervention during the index PCI procedure. Results Most older MI patients (91% STEMI and 74% NSTEMI) received culprit-only intervention during the index PCI. Among STEMI patients, multivessel intervention during the index PCI was associated with higher 30-day mortality (8.3% vs 6.3%, adjusted hazard ratio [HR] 1.36, 95% CI 1.14-1.62) than culprit-only intervention, and this trend persisted at 1 year (13.8% vs 12.2%, adjusted HR 1.14, 95% CI 0.99-1.31). No significant mortality differences were observed among NSTEMI patients at 30 days (3.4% vs 4.1%, adjusted HR 1.01, 95% CI 0.88-1.15) or at 1 year (10.1% vs 10.8%, adjusted HR 0.99, 95% CI 0.91-1.08). Conclusions Nonculprit intervention during the index PCI was associated with worse outcomes among STEMI patients, but not NSTEMI patients.
AB - Background Older adults presenting with acute myocardial infarction (MI) often have multivessel coronary artery disease amenable to percutaneous coronary intervention (PCI), yet the risks of multivessel intervention may outweigh potential benefits in these patients. We sought to determine if nonculprit intervention during the index PCI is associated with better outcomes among older patients with acute MI and multivessel disease. Methods We examined 19,271 ST-segment elevation MI (STEMI) and 31,361 non-STEMI (NSTEMI) patients 65 years or older with multivessel disease in a linked CathPCI Registry-Medicare database, excluding patients with prior coronary artery bypass grafting, left main disease, or cardiogenic shock. Using inverse probability-weighted propensity adjustment, we compared mortality between patients receiving culprit-only vs multivessel intervention during the index PCI procedure. Results Most older MI patients (91% STEMI and 74% NSTEMI) received culprit-only intervention during the index PCI. Among STEMI patients, multivessel intervention during the index PCI was associated with higher 30-day mortality (8.3% vs 6.3%, adjusted hazard ratio [HR] 1.36, 95% CI 1.14-1.62) than culprit-only intervention, and this trend persisted at 1 year (13.8% vs 12.2%, adjusted HR 1.14, 95% CI 0.99-1.31). No significant mortality differences were observed among NSTEMI patients at 30 days (3.4% vs 4.1%, adjusted HR 1.01, 95% CI 0.88-1.15) or at 1 year (10.1% vs 10.8%, adjusted HR 0.99, 95% CI 0.91-1.08). Conclusions Nonculprit intervention during the index PCI was associated with worse outcomes among STEMI patients, but not NSTEMI patients.
UR - http://www.scopus.com/inward/record.url?scp=84959309139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959309139&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2015.10.017
DO - 10.1016/j.ahj.2015.10.017
M3 - Article
C2 - 26856210
AN - SCOPUS:84959309139
SN - 0002-8703
VL - 172
SP - 9
EP - 18
JO - American Heart Journal
JF - American Heart Journal
ER -